>>Signaling Pathways>> Cancer Biology>>Deferitrin

Deferitrin (Synonyms: GT-56-252, (S)-4'-Hydroxydesazadesferrithiocin)

Catalog No.GC52316

An iron chelator and derivative of desferrithiocin

Products are for research use only. Not for human use. We do not sell to patients.

Deferitrin Chemical Structure

Cas No.: 239101-33-8

Size 가격 재고 수량
5 mg
US$455.00
재고 있음
10 mg
US$865.00
재고 있음
25 mg
US$2,045.00
재고 있음
50 mg
US$3,634.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Deferitrin is an iron chelator and a derivative of desferrithiocin that binds iron in a 2:1 (ligand:iron) ratio.1,2 It inhibits the proliferation of L1210 murine leukemia cells (IC50 = 17 µM).3 Deferitrin (150 µmol/kg) induces iron excretion in iron-overloaded C. apella monkeys and beagle dogs with an iron clearing efficiency (ICE) of 14.5 and 9.3%, respectively.2 It reduces fecal and urine iron levels by 607 and 357 µg/kg in C. apella monkeys and beagle dogs, respectively.

1.Bergeron, R.J., Wiegand, J., Bharti, N., et al.Desferrithiocin analogue iron chelators: Iron clearing efficiency, tissue distribution, and renal toxicityBiometals24(2)239-258(2011) 2.Bergeron, R.J., Wiegand, J., Weimar, W.R., et al.Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella)Comp. Med.54(6)664-672(2004) 3.Bergeron, R.J., Wiegand, J., Weimar, W.R., et al.Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrierChirality15(7)593-599(2003)

리뷰

Review for Deferitrin

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Deferitrin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.